Compare ITRM & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRM | PRPH |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 21.9M |
| IPO Year | 2018 | 1997 |
| Metric | ITRM | PRPH |
|---|---|---|
| Price | $0.47 | $0.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 3.2M |
| Earning Date | 11-14-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $390,000.00 | ★ $5,055,000.00 |
| Revenue This Year | N/A | $221.82 |
| Revenue Next Year | $325.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.12 |
| 52 Week High | $3.02 | $0.93 |
| Indicator | ITRM | PRPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 24.58 |
| Support Level | $0.40 | $0.12 |
| Resistance Level | $0.50 | $0.22 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 58.91 | 4.23 |
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.